5 Analysts Assess Elevance Health: What You Need To Know

Elevance Health ELV has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $477.08, along with a high estimate of $512.00 and a low estimate of $405.40. Marking an increase of 2.4%, the current average surpasses the previous average price target of $465.88.

Breaking Down Analyst Ratings: A Detailed Examination

The standing of Elevance Health among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

| Analyst | Analyst Firm | Action Taken | Rating |Current Price Target| Prior Price Target | |--------------------|--------------------|---------------|---------------|--------------------|--------------------| |Ann Hynes |Mizuho |Raises |Outperform | $505.00|$455.00 | |David Toung |Argus Research |Maintains |Hold | $405.40|$405.40 | |Stephen Baxter |Wells Fargo |Lowers |Overweight | $478.00|$483.00 | |Sarah James |Cantor Fitzgerald |Maintains |Overweight | $485.00|$485.00 | |Andrew Mok |Barclays |Raises |Overweight | $512.00|$501.00 |

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Elevance Health. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Elevance Health compared to the broader market.
• Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Elevance Health's stock. This comparison reveals trends in analysts' expectations over time.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Elevance Health's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Elevance Health analyst ratings.

Discovering Elevance Health: A Closer Look

Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 46 million medical members as of December 2024. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.

A Deep Dive into Elevance Health's Financials

Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.

Revenue Growth: Over the 3M period, Elevance Health showcased positive performance, achieving a revenue growth rate of 6.55% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 0.92%, the company may need to address challenges in effective cost control.

Return on Equity (ROE): Elevance Health's ROE excels beyond industry benchmarks, reaching 0.98%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Elevance Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.36% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: With a below-average debt-to-equity ratio of 0.76, Elevance Health adopts a prudent financial strategy, indicating a balanced approach to debt management.

Analyst Ratings: What Are They?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.